Status:
COMPLETED
Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in ERAS Programs for Radical Gastrectomy
Lead Sponsor:
JIANG Zhi-Wei
Conditions:
Gastric Cancer
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Patients with advanced gastric cancer received neoadjuvant chemotherapy undergo enhanced recovery after surgery (ERAS) programs.
Detailed Description
In recent years, enhanced recovery after surgery (ERAS) programs were applied in gastrectomy in areas with a high prevalence of gastric cancer, such as China and Japan, confirming that ERAS programs a...
Eligibility Criteria
Inclusion
- Patients with locally advanced gastric cancer.
- Age older than 18 and younger than 75 years.
- American Society of Anesthesiologists (ASA) class: I-III.
- Participants can describe the symptom objectively and cooperate actively.
- Written informed consent
Exclusion
- Patients allergic to oxaliplatin, tegafur gimerac etc.
- Patients with ischemic heart disease, cerebrovascular disease and peripheral vascular disease, or cardiac function \> II (NYHA)
- Patients with complications (bleeding, perforation and obstruction) caused by gastric cancer.
- Patients with severe liver and renal dysfunction (Child - Pugh ≥ 10; Cr \< 25 ml/min).
- Patients who require simultaneous surgery for other diseases.
- Patients who received upper abdominal surgery previously.
- Pregnant or breast-feeding women.
Key Trial Info
Start Date :
August 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 20 2016
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT03238404
Start Date
August 1 2015
End Date
December 20 2016
Last Update
August 3 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jinling Hospital, Medical School of Nanjing University
Nanjing, Jiangsu, China, 210002